daclizumab + mycophenolate mofetil + prednisolone

This is a combination immunosuppressive regimen consisting of daclizumab (a humanized monoclonal antibody targeting CD25 on activated T cells), mycophenolate mofetil (an inosine monophosphate dehydrogenase inhibitor), and prednisolone (a corticosteroid). This combination is primarily used to prevent organ rejection in transplant recipients, particularly in kidney transplantation. The regimen works through multiple mechanisms to suppress the immune response: daclizumab blocks IL-2 receptor signaling, mycophenolate mofetil inhibits lymphocyte proliferation, and prednisolone provides broad anti-inflammatory effects.